Grants and Contributions

Project activities include: (1) strengthening epidemiological surveillance; (2) supporting early and appropriate case management; (3) training health community workers; and (4) providing medical supplies and vaccinations as appropriate.

This Project aims to reduce the incidence of COVID-19 related death and serious illness, particularly amongst priority groups and vulnerable populations, by increasing equitable access to and uptake of COVID-19 vaccines in five countries in the African region. The Project will support health systems strengthening to enable the delivery of gender-equitable COVID-19 vaccination and routine health services.

Examples of livelihood-based anticipatory actions for agriculture include: (1) rehabilitating water harvesting systems and reinforcing river banks; (2) distributing conditional or unconditional cash transfers, crop varieties, animal feed and supplements; (3) protecting livestock including vaccination, animal health campaigns and evacuation; and (4) diversifying livelihood.

To be eligible to the competition, applications must be co-led by Canadian and African researchers and address all objectives:

• Provide rapid evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally;
• Undertake robust, multi-country cross learning, and comparative research (including in collaboration with other international researchers where appropriate) on:
o the safety and real-world effectiveness of medical or other countermeasures deployed* (including vaccines and therapeutics) to treat and/or prevent monkeypox infections in people in Canada and globally; and
o the underlying serological histories and transmission dynamics of the current monkeypox outbreaks in Canada and globally (including time of exposure and transmission during asymptomatic phase, mechanisms of human-to-human transmission, and key risk factors for infection and transmission);
• Align with and contribute to the WHO Global Clinical Platform for monkeypox and other international monkeypox surveillance and research coordination activities by:
o adopting WHO case investigation and reporting forms;
o developing robust study protocols that can be integrated and harmonized with international clinical datasets; and
o contributing to global real-time sharing and analyses of research findings across different study contexts
*Please note that medical countermeasures against monkeypox (including vaccines, drugs and other therapeutic agents) will not be provided by the Government of Canada for research supported through this funding opportunity.

To be eligible to the competition, applications must be co-led by Canadian and African researchers and address all objectives:

• Provide rapid evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally;
• Undertake robust, multi-country cross learning, and comparative research (including in collaboration with other international researchers where appropriate) on:
o the safety and real-world effectiveness of medical or other countermeasures deployed* (including vaccines and therapeutics) to treat and/or prevent monkeypox infections in people in Canada and globally; and
o the underlying serological histories and transmission dynamics of the current monkeypox outbreaks in Canada and globally (including time of exposure and transmission during asymptomatic phase, mechanisms of human-to-human transmission, and key risk factors for infection and transmission);
• Align with and contribute to the WHO Global Clinical Platform for monkeypox and other international monkeypox surveillance and research coordination activities by:
o adopting WHO case investigation and reporting forms;
o developing robust study protocols that can be integrated and harmonized with international clinical datasets; and
o contributing to global real-time sharing and analyses of research findings across different study contexts
*Please note that medical countermeasures against monkeypox (including vaccines, drugs and other therapeutic agents) will not be provided by the Government of Canada for research supported through this funding opportunity.

Development of a vaccine against avian flu.

This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.

Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.

Optimization of ultra-stable formulation for viral vectored vaccine, compatible with oral dosing

The World Customs Organization (WCO) is an independent intergovernmental body whose mission is to enhance the effectiveness and efficiency of customs administrations. The WCO currently has 177 member governments. A member of the WCO, Canada has taken a key role in areas such as trade facilitation, revisions to the Harmonized System, capacity building, combating counterfeiting and the development and implementation of the Framework of Standards to Secure and Facilitate Global Trade (SAFE). Canada’s contribution to the WCO advances its interests internationally, particularly given the importance of international trade for the Canadian economy.